Sökning: onr:"swepub:oai:DiVA.org:miun-51088" >
Molnupiravir for th...
-
Cheema, H. A.
(författare)
Molnupiravir for the treatment of COVID-19 outpatients : An updated meta-analysis
- Artikel/kapitelEngelska2024
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2024
-
electronicrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:miun-51088
-
https://urn.kb.se/resolve?urn=urn:nbn:se:miun:diva-51088URI
-
https://doi.org/10.1016/j.jmii.2024.03.002DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: The majority of available data on molnupiravir come from an unvaccinated COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence from recent randomized controlled trials (RCTs) as well as observational studies stratified by vaccination status to determine the clinical efficacy and safety of molnupiravir in COVID-19 outpatients. Methods: We searched PubMed, Embase, the Cochrane Library, medRxiv, and ClinicalTrials.gov from inception to November 2023. We conducted our meta-analysis using RevMan 5.4 with risk ratio (RR) as the effect measure. Results: We included 8 RCTs and 5 observational studies in our meta-analysis. Molnupiravir reduced the risk of all-cause mortality (RR 0.28; 95% CI: 0.20–0.79, I2 = 0%) but did not decrease the hospitalization rate (RR 0.67; 95% CI: 0.45–1.00, I2 = 53%) in the overall population; in the immunized population, no benefits were observed. Molnupiravir lowered the rate of no recovery (RR 0.78; 95% CI: 0.76–0.81, I2 = 0%) and increased virological clearance at day 5 (RR 2.68; 95% CI: 1.94–4.22, I2 = 85%). There was no increase in the incidence of adverse events. Conclusions: Molnupiravir does not decrease mortality and hospitalization rates in immunized patients with COVID-19. However, it does shorten the disease course and increases the recovery rate. The use of molnupiravir will need to be considered on a case-by-case basis in the context of the prevailing social circumstances, the resource setting, drug costs, and the healthcare burden.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Abdul Rab, S.
(författare)
-
Butt, M.
(författare)
-
Jafar, U.
(författare)
-
Shahid, A.
(författare)
-
Rehman, A. U.
(författare)
-
Lee, Ka YiuMittuniversitetet,Institutionen för hälsovetenskaper (HOV),Swedish Winter Sports Research Centre(Swepub:miun)kyllee
(författare)
-
Sahra, S.
(författare)
-
Sah, R.
(författare)
-
MittuniversitetetInstitutionen för hälsovetenskaper (HOV)
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Journal of Microbiology, Immunology and Infection: Elsevier BV57:3, s. 396-4021684-1182
Internetlänk
Hitta via bibliotek
Till lärosätets databas